China-based Impact Therapeutics (HKEX: 07630.HK) has signed an exclusive license agreement with UK-based Pharmanovia, granting the specialty pharma company rights to manufacture, develop, and commercialize senaparib across 66 countries spanning Europe, the Middle East and North Africa, Australia, and New Zealand. Pharmanovia is committing to payments worth up to EUR 423.5 million (USD 487.1 million), including undisclosed upfront payment, near-term regulatory milestones, and commercial milestones tied to sales thresholds, alongside tiered royalties of up to mid-twenties percent on net sales.
The deal comes shortly after Impact listed on the Hong Kong Stock Exchange Main Board in May 2026, and approximately six months before the expected European Medicines Agency (EMA) approval decision for senaparib. The EMA accepted Impact's Marketing Authorisation Application (MAA) for senaparib in August 2025 for first-line maintenance therapy in adult patients with advanced ovarian cancer. Senaparib received approval from China's National Medical Products Administration (NMPA) in January 2025 for the same indication and was included in China's National Reimbursement Drug List in December 2025.
Senaparib is a PARP1/2 inhibitor that the company describes as having a wide safety window derived from its molecular structure. The drug enters a crowded European field: olaparib (Lynparza, AstraZeneca/MSD) and niraparib (Zejula, GSK) are already established in the first-line ovarian cancer maintenance setting in Europe, while rucaparib was withdrawn from the EU market in 2022 following commercial difficulties. Impact claims senaparib delivered the most favorable progression-free survival outcome among PARP1/2 inhibitors in first-line maintenance for ovarian cancer "all-comers" in China on a non-head-to-head basis.
Pharmanovia specializes in acquiring and commercializing late-stage and approved medicines across international markets rather than discovering new drugs internally. The deal structure — signed ahead of EMA approval with near-term regulatory milestones likely triggered by that decision — is consistent with a pattern where licensors secure commercial partners before approval to enable rapid launch, while transferring some regulatory risk to the licensee in exchange for more favorable milestone economics. Pharmanovia demonstrated this model previously: it signed a licensing agreement with Germany-based Lindis Biotech for catumaxomab in November 2024 when that asset held a CHMP positive opinion, and subsequently received European marketing authorization for catumaxomab in February 2025. The senaparib transaction is structurally analogous but considerably larger in geographic scope and disclosed deal value.